Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2024-01-31 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
关于2024年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider information holders and incentive recipients' trading activities related to a 2024 restricted stock incentive plan. It details the scope, procedures, and conclusions of the investigation into stock trading by insiders and incentive recipients during a specified period. The document does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about compliance with insider trading rules and disclosure requirements, rather than a financial report or management discussion. The document length is short (1769 characters), and it is a formal announcement of an internal compliance check and stock trading activity related to insider information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-31 Chinese
2023年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2023 annual performance forecast (业绩预告) from Harbin Yuheng Pharmaceutical Co., Ltd. It provides estimated net profit figures for the full year 2023, compares them to the previous year, and explains the reasons for the changes. It also mentions communication with the auditor regarding the forecast. The document is relatively short (1633 characters) and does not contain full financial statements or detailed financial analysis. It is a forward-looking earnings preview rather than a full earnings release or annual report. According to the filing definitions, an Earnings Release (ER) is the initial announcement of quarterly or periodical financial results with key highlights only, which fits this document. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements. It is not a Report Publication Announcement (RPA) because it contains substantive forecast data, not just a notice of report availability. Therefore, the best classification is Earnings Release (ER). FY 2023
2024-01-30 Chinese
监事会关于2024年限制性股票激励计划首次授予激励对象名单的审核意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a public announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the supervisory board's review and public disclosure of the initial list of incentive recipients under the company's 2024 restricted stock incentive plan. It includes details about the legal and regulatory compliance of the incentive recipients, the public notice period, and the supervisory board's verification process. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement related to a stock incentive plan and the verification of the incentive recipients, which aligns with disclosures about share-based compensation plans and related approvals. This type of document is best classified under Regulatory Filings (RNS) as it is a regulatory announcement about compliance and internal governance related to stock incentives, not a full report or financial statement.
2024-01-25 Chinese
第六届监事会第九次会议决议公告暨关于2024年限制性股票激励计划相关事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board of Harbin Yuheng Pharmaceutical Co., Ltd. regarding resolutions passed in their ninth meeting of the sixth supervisory board. It discusses the review and approval of a 2024 restricted stock incentive plan and related matters, including voting results and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial data but rather reports on supervisory board decisions and opinions on incentive plans. It also references that detailed documents are disclosed elsewhere (on the cninfo website). The document length is short (2478 characters) and primarily serves as an official announcement of supervisory board resolutions and opinions related to stock incentive plans. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement and does not constitute a full report or financial statement.
2024-01-15 Chinese
关于独立董事公开征集委托投票权的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by an independent director of Harbin Yuheng Pharmaceutical Co., Ltd. regarding the solicitation of proxy voting rights for the company's 2024 first extraordinary general meeting. It details the process, conditions, and legal compliance for collecting proxy votes related to the 2024 restricted stock incentive plan proposals. The document includes the proxy authorization form and instructions for shareholders to delegate their voting rights. It is not a report of voting results, nor is it a notice of a meeting or a proxy solicitation statement in the traditional sense. Instead, it is a formal announcement of the independent director's public solicitation of proxy votes, which is a specific regulatory disclosure in Chinese securities practice. This fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement about proxy vote solicitation and does not fit the other more specific categories such as Proxy Solicitation & Information Statement (PSI) which typically involves materials sent to shareholders for voting, or Declaration of Voting Results (DVA) which reports vote outcomes. The document is over 5,000 characters and contains detailed procedural and legal information, not just a brief announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-01-15 Chinese
第六届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 11th meeting of the 6th Board of Directors of Harbin Yuheng Pharmaceutical Co., Ltd. It includes details about the approval of a 2024 restricted stock incentive plan, appointment of a financial officer, and the calling of an extraordinary shareholders meeting. The document contains voting results and biographical information about the appointed financial officer. It does not contain financial statements or detailed financial performance data. It is primarily about board decisions and management appointments. Therefore, it fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is a full announcement, not a brief notice or a report publication announcement.
2024-01-15 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.